"Wij richten ons op de patiënten in de regio Gooi en Vechtstreek en zijn een regionaal ziekenhuis met een focus op acuut klinische zorg."

During the past decade, Tergooi conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 4 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 2 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tergooi" #1 sponsor was "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 2 trials, followed by "Bayer" with 2 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tergooi" #1 collaborator was "Amsterdam UMC, location VUmc" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "ZonMw: The Netherlands Organisation for Health Research and Development" with 2 trials as a collaborator, "Aarhus University Hospital" with 1 trials as a collaborator and "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Tergooi" are "Coronary Artery Disease" (4 trials), "Heart Failure" (4 trials), "Atherosclerotic Cardiovascular Disease" (2 trials), "Cardiovascular Disease" (2 trials) and "Hypercholesterolemia" (2 trials). Many other conditions were trialed in "Tergooi" in a lesser frequency.

Most popular intervention types in "Tergooi" are "Drug" (15 trials), "Other" (6 trials), "Device" (4 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Empagliflozin" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Abbott Laboratories Xience" (1 trials) and "Abiraterone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tergooi" are 24 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Tergooi". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Tergooi, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Tergooi, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".